-
Mashup Score: 3Think Tank 2024 - Pancreatic Cancer | Johns Hopkins Pathology - 2 month(s) ago
The 10th Annual Sol Goldman Pancreatic Cancer Research Center Think Tank Hosted by Ralph Hruban, M.D., and Laura Wood, M.D., Ph.D. April 3, 2024 08:30 AM – 12:00 PM EST Jerome Cros Professor of Pathology Beaujon Hospital, Université Paris Cité To register in advance for this free webinar, click the button below. After registering, you will receive a confirmation email containing informati on about joining the webinar. Third Degree Relatives – First cousins, great-aunts and uncles Second Degree Relatives
Source: pathology.jhu.eduCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 3Flashback Foreword: Gemcitabine for Advanced Pancreatic Cancer - 4 month(s) ago
The trial by Burris et al 1 is a landmark study not only in the realm of pancreatic cancer but also in the larger field of clinical research. Its publication in the Journal of Clinical Onc ology in 1997 was a critical turning point and led to the first regulatory approval on the basis of an innovative quality-of-life instrument, engaged the research community in focusing on a disease in need of further study, and encouraged multiple stakeholders to consider greater investment to improve outcomes for this
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
RT @BenWestphalen: This @JCO_ASCO flashback comes with an editorial by @EileenMOReilly & team https://t.co/oOolDNRzkw
-
-
Mashup Score: 2Flashback Foreword: Gemcitabine for Advanced Pancreatic Cancer - 5 month(s) ago
The trial by Burris et al 1 is a landmark study not only in the realm of pancreatic cancer but also in the larger field of clinical research. Its publication in the Journal of Clinical Onc ology in 1997 was a critical turning point and led to the first regulatory approval on the basis of an innovative quality-of-life instrument, engaged the research community in focusing on a disease in need of further study, and encouraged multiple stakeholders to consider greater investment to improve outcomes for this
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
RT @BenWestphalen: This @JCO_ASCO flashback comes with an editorial by @EileenMOReilly & team https://t.co/oOolDNRzkw
-
-
Mashup Score: 3It's Pancreatic Cancer Awareness Month - 6 month(s) ago
Join us throughout the month of November as we shine a light on pancreatic cancer! Learn more about how to get involved at www.pancreatic.org/november
Source: www.youtube.comCategories: General Medicine News, Hem/OncsTweet-
RT @perilonthesea: It's Pancreatic Cancer Awareness Month @HirshbergFound https://t.co/5IbpdN8KfM via @YouTube
-
-
Mashup Score: 9Digital Academic Repository - University of Amsterdam - 6 month(s) ago
UvA-DARE (Digital Academic Repository) Author Title Left-sided pancreatic surgery Subtitle …
Source: dare.uva.nlCategories: General Medicine News, Hem/OncsTweet-
RT @MarcBesselink: Hora est! Today beautiful #PhD ceremony @WardvBodegraven “Left-sided pancreatic surgery” ➡️ https://t.co/5vM3G09fxB : g…
-
-
Mashup Score: 13AGA Clinical Practice Update on the Epidemiology, Evaluation, and Management of Exocrine Pancreatic Insufficiency: Expert Review - 6 month(s) ago
Exocrine pancreatic insufficiency (EPI) is a disorder caused by the failure of the pancreas to deliver a minimum/threshold level of specific pancreatic digestive enzymes to the intestine, leading to the maldigestion of nutrients and macronutrients, resulting in their variable deficiencies. EPI is frequently underdiagnosed and, as a result, patients are often not treated appropriately. There is an urgent need to increase awareness of and treatment for this condition. The aim of this American Gastroenterological Association (AGA) Clinical Practice Update Expert Review was to provide Best Practice Advice on the epidemiology, evaluation, and management of EPI.
Source: www.gastrojournal.orgCategories: General Medicine News, Hem/OncsTweet-
RT @Mon_ish_K: Best practice advice on the management of Exocrine Pancreatic Insufficiency https://t.co/dIstSOicT1
-
-
Mashup Score: 16Therapeutic developments in pancreatic cancer - Nature Reviews Gastroenterology & Hepatology - 6 month(s) ago
The incidence of pancreatic ductal adenocarcinoma (PDAC) is rising. In this Review, Hu and O’Reilly summarize the latest advances and clinical trials for the treatment of PDAC, including biomarkers, targeted therapies and immunotherapy as well as novel clinical trial designs. They also discuss emerging therapeutic options for this disease.
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
RT @SyedAAhmad5: Therapeutic developments in pancreatic cancer @NatureRevCancer @EileenMOReilly @SWOG https://t.co/rcLnuplssT
-
-
Mashup Score: 16Therapeutic developments in pancreatic cancer - Nature Reviews Gastroenterology & Hepatology - 6 month(s) ago
The incidence of pancreatic ductal adenocarcinoma (PDAC) is rising. In this Review, Hu and O’Reilly summarize the latest advances and clinical trials for the treatment of PDAC, including biomarkers, targeted therapies and immunotherapy as well as novel clinical trial designs. They also discuss emerging therapeutic options for this disease.
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
RT @SyedAAhmad5: Therapeutic developments in pancreatic cancer @NatureRevCancer @EileenMOReilly @SWOG https://t.co/rcLnuplssT
-
-
Mashup Score: 3Genomic Profiling Reveals Germline Predisposition and Homologous Recombination Deficiency in Pancreatic Acinar Cell Carcinoma - 7 month(s) ago
PURPOSE To determine the genetic predisposition underlying pancreatic acinar cell carcinoma (PACC) and characterize its genomic features. METHODS Both somatic and germline analyses were performed using an Food and Drug Administration–authorized matched tumor/normal sequencing assay on a clinical cohort of 28,780 patients with cancer, 49 of whom were diagnosed with PACC. For a subset of PACCs, whole-genome sequencing (WGS; n = 12) and RNA sequencing (n = 6) were performed. RESULTS Eighteen of 49 (36.7%) PACCs harbored germline pathogenic variants in homologous recombination (HR) and DNA damage response (DDR) genes, including BRCA1 (n = 1), BRCA2 (n = 12), PALB2 (n = 2), ATM (n = 2), and CHEK2 (n = 1). Thirty-one PACCs displayed pure, and 18 PACCs harbored mixed acinar cell histology. Fifteen of 31 (48%) pure PACCs harbored a germline pathogenic variant affecting HR-/DDR-related genes. BRCA2 germline pathogenic variants (11 of 31, 35%) were significantly more frequent in pure PACCs than
Source: ascopubs.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @JCO_ASCO: 🧐 Pancreatic acinar cell carcinoma is a #BRCA2 HRD-related cancer: https://t.co/JqkXx1uEVE #PancSM #DNArepair #genomics @Cent…
-
-
Mashup Score: 6Tumor Board Tuesday 2023 Conversations - 8 month(s) ago
Tumor Board Tuesdays is a regularly scheduled, Twitter-based case discussion forum led by expert faculty exploring cases in various solid tumor malignancies. The series will focus on practice application in the clinic. Experts will present recent data and focus on realistic case examples. The advantage to this format is the ability to comment and receive feedback from the experts.
Source: integrityce.comCategories: Latest Headlines, Oncologists1Tweet-
RT @TumorBoardTues: #TumorBoardTuesday Free #CME🔗 https://t.co/GzqzvikHrp Question2⃣ 🤔What Tx (🌟approved OR investigational🌟) would you…
-
RT @DerekAOReilly: #ArtificialIntelligence and #PancreaticCancer https://t.co/GvMSfpeNYI https://t.co/atO9JVOUIp